# Immunic, Inc.

**IMUX**

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001280776

# None

**No letter**

4 of 14 inputs computable; 7 are required, with a score in every sleeve

| Scoreboard | |
|---|---|
| **Reliability** | 0.83 AUC<br>filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025 |
| **Peer failure rate** | 1.07% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $12.5M to $120M assets<br>total assets $24.1M |
| **Warnings** | thin data<br>not computable: dilution, degenerate inputs, distress, fortress balance sheet |
| **Inputs computable** | 4 of 14 |
| **Graded from** | filings received through Apr 22, 2026<br>201 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026 |
| **Last close** | $7.79<br>2026-11-06; market equity $106.3M; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 26, 2026*

Immunic, Inc. ("Immunic," "we," "us," "our" or the "Company") is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases. We are headquartered in New York City with our main operations in Gräfelfing near Munich, Germany. We had 92 employees as of February 1, 2026. We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*

| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 11.4** | | | | | | |
| Gross profitability | not computable | 32.3% | | | | |
| *one or more required annual facts are missing* | | | | | | |
| Return on invested capital | not computable | 9.3% | | | | |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | |
|---|---|---|---|---|---|
| *one or more required annual facts are missing* | | | | | |
| Accruals ratio | (35.0%) | (6.6%) | 11.4 | 802 | 2025-12-31 |
| Gross margin stability, five years | not computable | 2.8 pts | | | |
| *five annual gross margins are required; found 0* | | | | | |
| **Solvency, sleeve percentile 93.9** | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | |
| Altman Z double-prime | (113.67) | (0.37) | 95.8 | 747 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | |
| *one or more required annual facts are missing* | | | | | |
| Interest coverage | not computable | (4.51x) | | | |
| *one or more required annual facts are missing* | | | | | |
| Current ratio | 0.75x | 2.94x | 92.0 | 828 | 2025-12-31 |
| **Growth and financing, sleeve percentile 97.4** | | | | | |
| Revenue growth, three-year compound | not computable | 10.0% | | | |
| *four annual observations are required; found 0* | | | | | |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | |
| Reinvestment rate | not computable | 37.1% | | | |
| *required facts have no common fiscal period end* | | | | | |
| Asset growth, three years | (42.7%) | 2.2% | 97.4 | 696 | 2025-12-31 |
| Net share issuance, one year | not computable | 2.5% | | | |
| *prior share count is 55 days earlier* | | | | | |

## Warnings

*1 of 7 checks triggered; none of them enters the letter*

| Check | Measured |
|---|---|
| Thin data | 4 of 14 grade factors are computable; minimum is 7 |

## What the price implies

*at the 2026-11-06 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 19.4% | (2.1%) | 62 |
| Distance from 52-week high | (54.1%) | (30.4%) | 27 |
| EBIT to enterprise value | not computable | (1.5%) | |
| Free cash flow yield | (81.3%) | (1.0%) | 8 |
| Book value to price | 1.21 | 0.29 | 90 |
| Sales to price | not computable | 0.30 | |
| Composite equity issuance, five years | 186.3% | 20.8% | 87 |
| Relative strength against the sector, log excess return | 0.01 | (0.19) | 62 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | fail |
| No new shares issued | fail |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | |
|---|---|
| Gross margin improved | fail |
| Asset turnover improved | fail |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $155.1M |
| Operating cash flow, four quarters | -$87.7M |
| Months of runway | 21.2 |
| Days since last periodic filing | 90 (10-Q received Aug 11, 2026) |
| Median daily dollar volume, 63 sessions | $3.1M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | net income | us-gaap:NetIncomeLoss | -$97.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 2 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$85.8M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 3 | assets | us-gaap:Assets | $24.1M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 4 | assets | us-gaap:Assets | $40.9M | 2024-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 5 | current assets | us-gaap:AssetsCurrent | $22.9M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 6 | current liabilities | us-gaap:LiabilitiesCurrent | $30.6M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 7 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$608.6M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 8 | operating income | us-gaap:OperatingIncomeLoss | -$103.2M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 9 | book equity | us-gaap:StockholdersEquity | -$6.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 10 | liabilities | us-gaap:Liabilities | $30.7M | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 11 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $161,000 | 2025-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 12 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$84.8M | 2024-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 13 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $264,000 | 2024-12-31 | 2026-02-26 | 10-K | 26-000005 |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$70.8M | 2023-12-31 | 2025-03-31 | 10-K | 25-000005 |
| 15 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $334,000 | 2023-12-31 | 2025-03-31 | 10-K | 25-000005 |
| 16 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$65.1M | 2022-12-31 | 2024-02-22 | 10-K | 24-000004 |
| 17 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $112,000 | 2022-12-31 | 2024-02-22 | 10-K | 24-000004 |
| 18 | assets | us-gaap:Assets | $54.3M | 2023-12-31 | 2025-03-31 | 10-K | 25-000005 |
| 19 | assets | us-gaap:Assets | $127.8M | 2022-12-31 | 2024-02-22 | 10-K | 24-000004 |
| 20 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 136,214,825 | 2026-04-16 | 2026-04-22 | 10-K/A | 26-000493 |
| 21 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 130,464,825 | 2026-02-20 | 2026-02-26 | 10-K | 26-000005 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.